未登录

R

Robert N. Bream

glaxosmithkline usa

H指数:10

被引数:1,349

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Learning from the EMA experience: common CMC deficiencies in marketing authorisation applications over the past decade

从EMA经验中学习：过去十年中营销授权申请中常见的CMC缺陷

Drug Discovery Today

IF7.5

2025-08-050

OAAI

Formation of N-Nitrosamine Drug Substance Related Impurities in Medicines: A Regulatory Perspective on Risk Factors and Mitigation Strategies

药物中N-亚硝胺原料药相关杂质的形成: 风险因素和缓解策略的监管视角

ORGANIC PROCESS RESEARCH & DEVELOPMENT

IF3.5

2023-07-2134

OA

Application of C-H Functionalization in the Development of a Concise and Convergent Route to the Phosphatidylinositol-3-kinase Delta Inhibitor Nemiralisib

ORGANIC PROCESS RESEARCH & DEVELOPMENT

IF3.5

2021-02-0911

PREAI

Development of Flexible and Scalable Routes to Two Phosphatidinylinositol-3-kinase Delta Inhibitors via a Common Intermediate Approach

ORGANIC PROCESS RESEARCH & DEVELOPMENT

IF3.5

2018-02-2710

PREAI

Design and Application of a DNA-Encoded Macrocyclic Peptide Library

ACS CHEMICAL BIOLOGY

IF3.8

2017-12-0489

PREAI

Development of Synthetic Routes, via a Tropinone Intermediate, to a Long-Acting Muscarinic Antagonist for the Treatment of Respiratory Disease

ORGANIC PROCESS RESEARCH & DEVELOPMENT

IF3.5

2013-03-2710

PREAI

Development of a Selective Friedel-Crafts Alkylation Surrogate: Safe Operating Conditions through Mechanistic Understanding

ORGANIC PROCESS RESEARCH & DEVELOPMENT

IF3.5

2012-10-051

PREAI

Asymmetric allylic alkylation of cyclic vinylogous esters and thioesters by Pd-catalyzed decarboxylation of enol carbonate and β-ketoester substrates

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

IF16.9

2006-04-27157

PREAI

Synthesis of the β2 agonist (R)-salmeterol using a sequence of supported reagents and scavenging agents

ORGANIC LETTERS

IF5

2002-10-0934

PREAI